Our Pipeline

Our Pipeline – Overview

Crescendo is developing novel Humabody® therapeutics capable of delivering safer, more durable anti-cancer responses in patients with hard-to-treat cancers. Its pipeline has broad applicability across a range of key oncology indications with a focus on novel, targeted T cell activation.

CB307: a first-in-class PSMA-specific T cell enhancer

Leading its proprietary pipeline, Crescendo has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a safer, more durable anti-cancer effect. The clinical trial for CB307 is underway in patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT04839991).

Addressing an unmet patient need in prostate cancer

Prostate cancer is the most common cancer in men, with up to 1 in 8 being diagnosed with it within their lifetime1. For those with the most severe mCRPC, who have already attempted multiple lines of treatment and who tend to be elderly and fragile, there are limited options. Targeted immunotherapy can be effective, better tolerated and longer lasting, and has great potential to address this unmet medical need. However, at present, there are no widely approved immunotherapy drugs for this indication. Crescendo is focused on addressing this patient group with an ongoing Phase Ib clinical trial investigating its lead programme, CB307, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).

1 Note: the numbers presented are for US and EU27 countries. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, https://gco.iarc.who.int/today (accessed 27 February 2024).